Issues in Oncology
Skin Cancer

Disparities in Melanoma Outcomes Among Black Patients

Investigators may have uncovered sex-based disparities in the detection and survival of melanoma in Black patients according to a recent study published...

Breast Cancer
Issues in Oncology
Geriatric Oncology

Chemotherapy May Accelerate Physical Decline in Older Patients With Early-Stage Breast Cancer

Investigators have found that female patients aged 65 years or older with high-risk breast cancer who are treated with chemotherapy may be more likely to...

Kidney Cancer

Marker for Distinguishing Renal Cell Carcinoma From Benign Renal Masses

In a study reported in the Journal of Clinical Oncology, Xu et al found that higher levels of preoperative plasma kidney injury molecule-1 (pKIM-1) distinguished renal cell...

Gynecologic Cancers
Colorectal Cancer
Head and Neck Cancer

FDA Approves HPV Self-Collection Solution

On May 15, Roche announced the U.S. Food and Drug Administration (FDA) approval of its human papillomavirus (HPV) self-collection solution—one of the first...


Previously Untreated Mantle Cell Lymphoma: Ibrutinib, Immunochemotherapy, and ASCT

As reported in The Lancet by Martin Dreyling, MD, PhD, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate...


Sponsored Content

More Top Stories

Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Prostate Cancer

A Delay in Diagnosis Led to Advanced Prostate Cancer

Cancer is not an unfamiliar disease to me. My mother died of cancer when I was 12. My oldest sister died of breast cancer, an aunt died of cancer (I don’t know which type), and my older brother is a prostate cancer survivor. So, when I was diagnosed with prostate cancer in October 2021, the news...


Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival?

Results from the Prognostic Immunophenotyping in Myeloma Response (PRIMeR) study, reported in the Journal of Clinical Oncology by Marcelo C. Pasquini, MD, MS, and colleagues, found that undetectable measurable residual disease (MRD) status at 1 year after autologous hematopoietic cell...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Hepatobiliary Cancer

Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer

On October 31, 2023, pembrolizumab (Keytruda) was approved for use with ­gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on the double-blind KEYNOTE-966 trial...

NIH’s New Cancer Screening Research Network and Cancer Screening Technologies

The National Institutes of Health (NIH) has launched the Cancer Screening Research Network, a clinical trials network to evaluate emerging cancer screening technologies. The new network will support the Biden-Harris Administration’s Cancer Moonshot initiative by investigating how to identify cancer ...

Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer: Comparison of Agents

In a Chinese phase III trial (CRTCOESC) reported in the Journal of Clinical Oncology, Jia et al found that neither capecitabine nor XELOX (capecitabine, oxaliplatin) improved 2-year overall survival vs cisplatin/fluorouracil as part of definitive concurrent chemoradiotherapy in patients with...

Hematologic Malignancies

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin


Pirtobrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

On December 1, 2023, pirtobrutinib (Jaypirca), a selective, noncovalent  Bruton’s tyrosine kinase (BTK) inhibitor that inhibits both wild-type and C481-mutant BTK with equal low nanomolar potency and is designed to address several of the limitations of covalent BTK inhibitors, was granted...


FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC

On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tarlatamab-dlle (Imdelltra), a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, for patients with extensive-stage small cell lung cancer (SCLC) with disease progression on or after...